On March 10, 2021 LAVA Therapeutics B.V., a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers (bs TCE) to transform cancer therapy, reported that a poster featuring lead clinical candidate LAVA-051 will be presented at week 1 of the virtual American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, which will be held April 10-15, 2021 (Press release, Lava Therapeutics, MAR 10, 2021, View Source [SID1234576403]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The following abstract is now available on the AACR (Free AACR Whitepaper) website at www.aacr.org.
Title: Potent anti-tumor activity against patient CLL, MM and AML cells by LAVA-051, a bispecific Vγ9Vδ2-T and type 1 NKT cell engager targeting CD1d
Session Type: E-Poster Session
Session Title: Therapeutic Antibodies, Including Engineered Antibodies
Abstract Number: 1855
LAVA-051 is a humanized gamma-delta bsTCE which targets CD1d and the Vδ2 domain of the T cell receptor. It is the first antibody-based compound targeting CD1d to activate both Vγ9Vδ2-T and type 1 NKT cells. LAVA-051 exerted substantial antitumor activity against patient derived acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) cells that express CD1d. In addition, improved survival was observed in in vivo AML and MM mouse xenograft models treated with LAVA-051.
LAVA-051 is planned to enter a Phase I/IIa study in hematologic malignancies in 1H 2021.